Effects of levosimendan on patients undergoing valve replacement
10.7507/1007-4848.201809036
- VernacularTitle:左西孟旦在心脏瓣膜置换术后患者中的应用
- Author:
SHENG Wei
1
;
LI Na
2
;
CHI Yifan
1
;
NIU Zhaozhuo
1
;
ZHANG Wenfeng
1
;
WU Jiantao
1
;
LI Haoyou
1
;
WANG Tianyi
1
;
HUANG Qiang
1
Author Information
1. Department of Cardiovascular Surgery, Qingdao Municipal Hospital, Medical College of Qingdao University, Qingdao, 266071, Shandong, P.R.China
2. Department of Emergency Cardiology, Qingdao Municipal Hospital, Medical College of Qingdao University, Qingdao, 266071, Shandong, P.R.China
- Publication Type:Journal Article
- Keywords:
Levosimendan;
valve replacement;
cardiac function
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2019;26(7):693-697
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of postoperative use of levosimendan on patients with valve replacement. Method Patients with valvular diseases who underwent valve replacement were prospectively enrolled during Jan 2014 to May 2018 in Qingdao Municipal Hospital, randomized to a levosimendan-treated group (n=93) and a control group (n=92) preoperatively. Patients in both groups underwent the same routine treatment preoperatively and postoperatively. In addition, patients in the levosimendan-treated group underwent levosimendan intravenous infusion 24 hours after entering ICU postoperatively. The clinical effect of the two groups was compared. Results Compared to the control group, the cardiac output(CO, 5.2±1.0 L/min vs. 4.4±1.1 L/min on the seventh day after surgery) and left ventricular ejection fraction (LVEF, 55.7%±2.5% vs. 50.5%±2.2% on the seventh day after surgery) of levosimendan-treated group were increased significantly at different time points(1 day, 3 days and 7 days after surgery)(P<0.05), and the brain natriuetic peptid (BNP) level (312.5±34.6 pg/ml vs. 455.4±45.2 pg/ml on the seventh day after surgery) was less than that of the control group (P<0.05). The dosage (11.5±1.8 mg/kg vs. 20.4±2.1 mg/kg) and administration time of vasoactive agents in the levosimendan-treated group were significantly lower or shorter than those in the control group (70.4±11.2 h vs. 110.5±12.1 h, P<0.05). The ICU stay length, and the total incidence of adverse events were less than those of the control group (P<0.05). Conclusion Postoperative use of levosimendan immediately after surgery can significantly improve the cardiac function status of patients who underwent valve replacement, reduce the dosage of vasoactive agents, shorten the time of ICU hospitalization, reduce the incidence of adverse events and enhance the patient’s recovery after valve replacement.
